We are a clinical stage genetic medicines company on a mission to improve the lives of patients with neurodegenerative diseases. Our primary focus is the development and advancement of cutting-edge, one-time therapies designed to target the underlying pathology of these conditions.
Our lead product candidate, PBFT02, seeks to treat neurodegenerative conditions, including frontotemporal dementia, by elevating progranulin levels to restore lysosomal function and slow disease progression. Our team's unwavering commitment to excellence is the driving force behind our mission to protect patients and their families against loss in neurodegenerative conditions.
Company Details
- Employees
- 59
- Founded
- -
- Address
- 2005 Market Street,
- Phone
- 267-866-0311
- in****@****bio.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- passagebio.com
- HQ
- Philadelphia, Pennsylvania
Passage Bio Questions
Passage Bio's helpline number is 267-866-0311
Passage Bio's website is passagebio.com
Passage Bio's LinkedIn profile is https://www.linkedin.com/company/passage-bio
Passage Bio has
59 employees.
View email and phone details for 59
employees at Passage Bio.
Passage Bio's industry is
Biotechnology Research
Passage Bio's top competitors are
Verismo Therapeutics,
Century Therapeutics, Inc,
Interius Biotherapeutics,
Carisma Therapeutics,
Capstan Therapeutics,
Aro Biotherapeutics,
Spark Therapeutics, Inc.,
Adaptimmune,
Swanbio Therapeutics,
Cabaletta Bio.
Passage Bio's support email address is info@passagebio.com
Passage Bio's categories are Biotechnology Research
Passage Bio's founding year is 2017
